Influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism

ZHIRONG ZHANG1*, WEIJI YANG2*, RONGBIAO YING3*, YING SHI1*, HUIFANG JIANG4*, DANLI CAI1*, JING KUANG1*, RUHUI YANG5* and LINGCONG WANG1

1Department of ICU, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006; 2Postgraduates Department of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053; 3Department of Surgical Oncology, Tumor Hospital of Taizhou, Wenling, Zhejiang 317500; 4Department of Hematology, Tongde Hospital of Zhejiang, Hangzhou, Zhejiang 310012; 5College of Medicine and Health, Lishui University, Lishui, Zhejiang 323000, P.R. China

Received August 31, 2016; Accepted April 19, 2017

DOI: 10.3892/ijmm.2017.2969

Abstract. The present study aimed to explore the influence of aspirin on the CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism (APE) in rats. Our previous study found that CX3CL1/CX3CR1 was increased in APE. However, the effect of this signaling pathway on APE remains unclear. CX3CL1-shRNA adenovirus and CX3CL1-overexpression vector were constructed. Male Sprague-Dawley rats were randomly divided into 9 groups (n=10): normal group (group N), sham operation group (group Sham), sham operation + aspirin group (group ASP), model group (group M), model + ASP group (group M+A), model + shRNA group (group M+SH), sham operation + CX3CL1-overexpression vector group (group Sham+CX3), model + ASP + shRNA group (group M+AS+SH), and model + ASP + CX3CL1-overexpression vector group (group M+A+CX3). Arterial pressure detection, hematoxylin and eosin staining, reverse transcription-polymerase chain reaction, enzyme-linked immunosorbent assay, and laser confocal scanning microscopy were applied. Aspirin significantly decreased pulmonary artery pressure, improve pathological changes in the embolism, and decreased the expression of CX3CL1/CX3CR1 and CX3CL1/NF-κB. Moreover, the adenovirus-overexpression CX3CL1 vector aggravated the inflammatory changes in APE, which were improved by aspirin. However, the intervention of the adenovirus CX3CL1 vector reduced the change, while its combination with aspirin significantly improved the change. In conclusion, aspirin improved pathological changes in rats with APE via the CX3CL1/CX3CR1 signaling pathway.

Introduction

Acute pulmonary embolism (APE) is a disease caused by various emboli blocking the pulmonary artery, leading to pulmonary circulation disorder. The morbidity and fatality rate are high in European and American countries, and have increased in recent years. The morbidity in the United States during 1979-1999 was reported to be 0.4%, and ~150,000 individuals are hospitalized due to APE every year. There was no obvious change in 20 years (1). The epidemiology of APE is difficult to confirm due to the lack of symptoms and proper diagnosis. In 2004, according to the demographic statistics of 454.4 million people in 6 countries of the European Union, 317,000 deaths related to venous thrombus were reported. Among them, 34% died of acute fat embolism, 59% died of APE (diagnosed by autopsy, not alive), and only 7% were diagnosed with APE prior to death (2). In China, of the 16,972,182 hospitalized patients, 18,206 patients had APE. The annual occurrence rate is 0.1%, and the incidence is significantly higher in males (0.2%) than in females (0.1%). The fatality rate are high in European and American countries, and have increased in recent years. The morbidity in the United States during 1979-1999 was reported to be 0.4%, and ~150,000 individuals are hospitalized due to APE every year. There was no obvious change in 20 years (1). The epidemiology of APE is difficult to confirm due to the lack of symptoms and proper diagnosis. In 2004, according to the demographic statistics of 454.4 million people in 6 countries of the European Union, 317,000 deaths related to venous thrombus were reported. Among them, 34% died of acute fat embolism, 59% died of APE (diagnosed by autopsy, not alive), and only 7% were diagnosed with APE prior to death (2). In China, of the 16,972,182 hospitalized patients, 18,206 patients had APE. The annual occurrence rate is 0.1%, and the incidence is significantly higher in males (0.2%) than in females (0.1%). The fatality rate of APE has become a common cardiovascular disease in China, seriously threatening human health. Thus, interventions are urgently needed.

Previous research found that the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-8, CX3CL1,
CX3CR1, nuclear factor-κB (NF-κB), extracellular signal-regulated kinase (ERK), PI3K/Akt, brain natriuretic peptide (BNP), troponin T (TnT) and D-dimer (D2D) were significantly increased in APE rat models (4-6). The increased CX3CL1 level in serum was found to have a positive correlation with serum IL-8 and TNF-α, and aspirin significantly inhibited all the aforementioned factors. Meanwhile, it was also found that aspirin could inhibit lipopolysaccharide and induce the expression of PI3K, Akt, ERK, NF-κB, CX3CL1, matrix metalloproteinase-7 (MMP-7) and MMP-12 in human bronchial epithelial cells (7). Therefore, it is believed that the inflammatory response occurs in APE, CX3CL1/CX3CR1 significantly increases, and TNF-α stimulates CX3CL1, and aspirin can inhibit the aforementioned factors. However, the effect of the CX3CL1/CX3CR1 signaling pathway on the occurrence of APE remains unclear.

In the present study, CX3CL1-short hairpin RNA (shRNA) adenovirus (AD) and CX3CL1-overexpression vector were constructed. Reverse transcription-polymerase chain reaction (RT-PCR), enzyme-linked immunosorbent assay (ELISA), laser confocal scanning microscopy, and pulmonary artery pressure detection were applied to explore the protective effect of aspirin on APE via the CX3CL1/CX3CR1 signaling pathway in an animal model.

Materials and methods

Materials. Enteric-coated aspirin tablets were procured from Nanjing Baijingyu Pharmaceutical Co., Ltd. (Jiangsu, China; drug specifications: 25 mg x 100 pills/bottle, batch no. 141201).

Male Sprague-Dawley (SD) rats (200 g) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China) and Vital River Laboratories Co., Ltd. (Beijing, China). The feeding temperature was 20-25°C, and the humidity was 40-70%. After a 6-day acclimation, the experiment was initiated. The study was approved by the Ethics Committee of Zhejiang Chinese Medical University.

Construction of the CX3CL1-overexpression vector and shRNA was performed. Vector pHBAd-murine cytomegalovirus (MCMV)-green fluorescent protein (GFP) and vector pHBAd-U6-GFP (Hanbio, Hangzhou, China) were used. Escherichia coli strain DH5α (Tiangen, Beijing, China), restriction enzymes, T4 ligase (both from Fermentas, Waltham, MA, USA), and plasmid DNA extraction kit (CWBio, Beijing, China) were used.

Biological function experimental system (BL-420S) and animal ventilator (HX-300) were obtained from Taimeng (Sichuan, China). Multiskan spectrum microplate spectrophotometer (Spectra Plus 384) was purchased from Molecular Devices (Sunnyvale, CA, USA).

Hematoxylin and eosin staining (H&E) was used to observe histopathological changes in the pulmonary tissue.

Thromboxane A2 (TXA2), troponin I type 3 (TNNI3), BNP and D2D levels in rat serum were detected using ELISA. TTNIN3kit, BNP, TXA2 and D2D were obtained from Youershengke (Wuhan, China).

RT-PCR was used to detect CX3CL1, CX3CR1 and intercellular adhesion molecule-1 (ICAM-1) expression in mRNA of rat pulmonary tissue. A high-purity total RNA rapid extraction kit was obtained from Generay (Shanghai, China), and a PrimeScript RT reagent kit was purchased from Takara (Tokyo, Japan). Super Real PreMix Plus (with SYBR-Green I) was obtained from Tiangen. High-precision spectrophotometer (Merinton SMA4000; Merinton Instrument, Ltd., Beijing, China) and quantitative PCR system (CFX connect real-time PCR system; Bio-Rad, Hercules, CA, USA) were used.

Laser confocal scanning microscopy was used to detect the coexpression of CX3CL1/CX3CR1 and CX3CL1/ NF-κB. Fractalkine antibody (CX3CL1) (cat. no. sc-7227; batch no. B1612; 1:10; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), anti-NF-κB p65 antibody (cat. no. ab7970; batch no. GR187946-6; 1:50), anti-CX3CR1 antibody (cat. no. ab8021; batch no. GR90085-11; 1:100) (both from Abcam, Cambridge, MA, USA), anti-rabbit IgG secondary antibody (cat. no. A21206; batch no. 1100071; 488 conjugate; Life Technologies, Carlsbad, CA, USA; excitation wavelength/emission wavelength: 488/520 nm, 1:200), anti-goat IgG secondary antibody (cat. no. A21432; batch no. I620248; 555 conjugate; excitation wavelength/emission wavelength: 555/562 nm, 1:200) (Life Technologies), 4',6-diamidino-2-phenylindole (DAPI) (excitation wavelength/emission wavelength: 358/461 nm; Sigma, St. Louis, MO, USA) were used.

Methods

Preparation of the CX3CL1-overexpression vector and shRNA. The steps for construction of CX3CL1 overexpression AD are as follows. AD vector plasmid was recombinated and pHBAd-MCMV-GFP vector was digested with EcoRI and BamHI double enzymes and collected after digestion. CX3CL1 fragments were obtained, and the transformed CX3CL1 was used to select bacterial colonies. The bacteria were incubated by shaking for 14 h at 37°C and 250 rpm. The bacterial suspension was detected using PCR and sequenced to obtain pHBAd-MCMV-GFP-CX3CL1 recombinant vector, marked as AD-CX3CL1. Meanwhile, plasmid pHBAd-MCMV-GFP was used as the control, and marked as AD-GFP. Recombinant plasmids and recombinant AD vector package were prepared. Then, virus harvesting, amplification, purification, and detection of the infectious titer were performed. CX3CL1 shRNA AD construct, screen and identify CX3CL1 shRNA (Fig. 1).

Animal model. Male SD rats (200±20 g) were randomly divided into 9 groups (n=10): normal group (group N), sham operation group (group Sham), sham operation + aspirin group (group ASP), model group (group M), model + ASP group (group M+A), model + shRNA group (group M+SH), sham operation + CX3CL1-overexpression vector group (group Sham+CX3), model + ASP + shRNA group (group M+A+SH), and model + ASP + CX3CL1-overexpression vector group (group M+A+CX3). Autologous thrombus was injected through the jugular vein to copy a rat PTE model. One day before surgery, 0.2 ml of blood was withdrawn from the caudal vein, and incubated at 37°C overnight. The concretionary thrombus was taken out to prepare a 2-ml syringe. The rats were anesthetized using 10% chloral hydrate (0.3 g/kg). The right jugular vein was separated, and the puncture needle was placed. The prepared embolus was pushed into the common vein using the puncture needle, followed by
pushing 1 ml of saline to prevent the embolus from staying in the tube or jugular vein. Finally, the wound was sutured after the bleeding stopped. One day before surgery and 40 min before modeling, the drug was administrated via gavage. The virus intervention groups (group M+SH, group Sham+CX3, group M+A+SH, group M+A+CX3) were injected once with aspirin 300 mg/kg through the caudal vein 3 days before modeling (109 pfu/rat). Group Sham and group M received an equal volume of saline every day. Group N did not receive any intervention.

**Detection of pulmonary artery pressure.** Six hours after modeling, the animals were anesthetized again. A PE50 tube was inserted into the pulmonary artery, and the other side was connected with a pressure transducer. A waveform of pulmonary artery pressure was recorded using the biological function experimental system (BL-420S), and pulmonary arterial systolic pressure (PASP), pulmonary artery diastolic pressure (PADP) and pulmonary arterial pressure (PAP) were calculated.

Pulmonary pathology was detected using H&E staining and CX3CL1, CX3CR1 and ICAM-1 in pulmonary tissue were detected by RT-PCR.

**Statistical analysis.** SPSS 21.0 (SPSS, Chicago, IL, USA) was used for data analysis, and the results are expressed as mean ± standard deviation. One-way analysis of variance was used, and pairwise comparison between groups was analyzed by least significant difference. A P-value <0.05 was considered to indicate a statistically significant result.

**Results**

**Detection of pulmonary artery pressure.** Compared with group N, hear rate (HR), PASP, PADP and PAP in group M were significantly increased (P<0.05). PASP and PAP in group Sham+CX3 were significantly increased (P<0.05). Compared with group M, HR in group M+A was significantly decreased (P<0.05), PASP in groups M+A+SH, ASP and M+A+CX3 were also significantly decreased (P<0.05). PADP and PAP in groups ASP, M+A, M+A+SH, and M+A+CX3 were significantly decreased (P<0.05) (Fig. 2).

**Pulmonary H&E detection.** The results of lung pathology as detected by H&E are shown in Table I and Fig. 3. CX3CL1, CX3CR1 and ICAM-1 in the pulmonary tissue as detected by PCR.

**Statistical analysis.** SPSS 21.0 (SPSS, Chicago, IL, USA) was used for data analysis, and the results are expressed as mean ± standard deviation. One-way analysis of variance was used, and pairwise comparison between groups was analyzed by least significant difference. A P-value <0.05 was considered to indicate a statistically significant result.

**Results**

**Detection of pulmonary artery pressure.** Compared with group N, hear rate (HR), PASP, PADP and PAP in group M were significantly increased (P<0.05). PASP and PAP in group Sham+CX3 were significantly increased (P<0.05). Compared with group M, HR in group M+A was significantly decreased (P<0.05), PASP in groups M+A+SH, ASP and M+A+CX3 were also significantly decreased (P<0.05). PADP and PAP in groups ASP, M+A, M+A+SH, and M+A+CX3 were significantly decreased (P<0.05) (Fig. 2).

**Pulmonary H&E detection.** The results of lung pathology as detected by H&E are shown in Table I and Fig. 3.

**CX3CL1, CX3CR1 and ICAM-1 in the pulmonary tissue as detected by PCR.** As shown in Fig. 4, compared with group N, CX3CL1 in groups M, Sham+CX3, M+A+SH and M+A+CX3 was significantly increased (P<0.05). Compared with group M, CX3CL1 in groups N, Sham, M+SH, ASP and M+A was significantly decreased (P<0.05).

**TXA2, TNNI3, BNP and D2D levels in rat serum as detected by ELISA.** As shown in Fig. 5, compared with group N, TXA2 in group M was significantly increased (P<0.05). Compared with group M, TXA2 in groups N, Sham, M+SH, ASP, M+A and M+A+SH was significantly decreased (P<0.05).
Figure 2. Detection of pulmonary artery pressure. *P<0.05 compared with group N; †P<0.05 compared with group M. PASP, pulmonary arterial systolic pressure; PADP, pulmonary artery diastolic pressure; PAP, pulmonary arterial pressure.

Table I. Pulmonary pathology as detected by hematoxylin and eosin (H&E).

<table>
<thead>
<tr>
<th>Group</th>
<th>Pathological change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group N</td>
<td>Clear pulmonary structure, normal alveolar structure, no evident inflammatory cell infiltration in pulmonary interstitial fibrosis, occasional inflammation in airways and blood vessels, no formation of thromboembolism in blood vessels</td>
</tr>
<tr>
<td>Group Sham, ASP and Sham+CX3</td>
<td>Same as normal group, less inflammatory cell infiltration in bronchus and blood vessels and pulmonary interstitial fibrosis (granulocytes, lymphocytes, and eosinophilic granulocytes), no evident formation of thromboembolism in blood vessels</td>
</tr>
<tr>
<td>Group M</td>
<td>Mixed thrombus and coagulation in the pulmonary artery, evident vascular endothelial loss, alveolar septal thickening and swelling, pulmonary hemorrhage, severe inflammatory cell infiltration in the bronchus and blood vessels and pulmonary interstitial fibrosis, or even pulmonary abscess</td>
</tr>
<tr>
<td>Group M+SH</td>
<td>Part of embolism in pulmonary artery dissolved, revascularization, intravascular subcutaneous hyperplasia with slight inflammation, less number of thrombogenesis, good thrombolytic effect</td>
</tr>
<tr>
<td>Group M+ASP</td>
<td>Good thrombolytic effect, evident vascular endothelial hyperplasia, severe inflammation</td>
</tr>
<tr>
<td>Group M+ASP+SH</td>
<td>Good thrombolytic effect, less inflammatory response</td>
</tr>
<tr>
<td>Group M+ASP+CX3</td>
<td>Good thrombolytic effect, more inflammatory response</td>
</tr>
</tbody>
</table>
Compared with group N, TNNI3 in group M+SH was significantly increased (P<0.05). Compared with group M, no significant difference was observed.

Compared with group N, BNP in group M was significantly increased (P<0.05). Compared with group M, BNP in groups N, Sham, ASP, M+A+SH, and M+A+CX3 was significantly decreased (P<0.05).

Compared with group N, D2D in groups M and M+SH was significantly increased (P<0.05). Compared with group M, D2D in groups N and M+A+SH was significantly decreased (P<0.05).

Coexpression of CX3CL1/CX3CR1 and CX3CL1/NF-κB as detected by laser confocal scanning microscopy. The positive color of immunofluorescence indicated that CX3CL1 (red) and CX3CR1 (green) were mainly expressed in the cytoplasm and cytomembrane. NF-κB (green) was mainly expressed in the cytoplasm, and rarely expressed in the cell nucleus. As shown...
in Tables II and III and Fig. 6, the fluorescence strength of each group was compared according to the following standard: slight, +; moderate, ++; strong, +++.

**Virus infection of the rat pulmonary tissue as observed by laser confocal scanning microscopy.** The pulmonary tissue infected by the virus is shown in green color, and the cell nucleus is shown in blue color (Fig. 7).

**Discussion**

In the present study, CX3CL1-shRNA AD and CX3CL1-overexpression vector were constructed. The study aimed to investigate the influence of CX3CL1 on APE. Compared with a previous study, this study detected pulmonary artery pressure. Although the pressure was not as visual as CTPA, it still could reflect the pressure change after APE. To directly observe the correlation between CX3CL1 in the APE site and CX3CR1 expression and the correlation between the change in the CX3CL1/CX3CR1 signaling pathway and NF-κB inflammatory pathway, laser confocal scanning microscopy was used. Due to the use of many groups, the experiment was divided into three steps: i) group N, group Sham, group M and group M+A; ii) group M, group M+SH and group M+CX3; iii) group M+SH, group M+CX3, group M+A+SH and group M+A+CX3.

### Table II. CX3CL1/CX3CR1 expression as detected by double-labeling immunofluorescence.

<table>
<thead>
<tr>
<th>Group</th>
<th>Expression strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group N and ASP</td>
<td>+</td>
</tr>
<tr>
<td>Group Sham, Sham+CX3 and M</td>
<td>++</td>
</tr>
<tr>
<td>Group M+A, M+A+SH and M+A+CX3</td>
<td>++</td>
</tr>
<tr>
<td>Group M+SH</td>
<td>+++</td>
</tr>
</tbody>
</table>

### Table III. CX3CL1/NF-κB expression as detected by double-labeling immunofluorescence.

<table>
<thead>
<tr>
<th>Group</th>
<th>Expression strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group N, ASP, Sham, and Sham+CX3</td>
<td>+</td>
</tr>
<tr>
<td>Group M+A, M+A+SH and M+A+CX3</td>
<td>++</td>
</tr>
<tr>
<td>Group M and M+SH</td>
<td>+++</td>
</tr>
</tbody>
</table>

NF-κB, nuclear factor-κB.
The first step focused on the drug effect and change in the signaling pathway, the second confirmed the influence of the change in the inflammatory pathway on APE (especially the change in proteins of the signaling pathway), and the third investigated the relationship between the signaling pathway and aspirin (especially the change in the signaling pathway). It was found that aspirin significantly decreased the pulmonary artery pressure, improved pathological changes in the embolism, and decreased the expression of the CX3CL1/CX3CR1 and CX3CL1/NF-κB signaling pathways. Moreover, the AD overexpression CX3CL1 vector aggravated the inflammatory changes in rats with APE, which were improved by aspirin. However, AD CX3CL1 intervention decreased this change, and its combination with aspirin significantly improved the APE changes.

The present study explored the important role of the CX3CL1/CX3CR1 signaling pathway in the occurrence of APE as well as improvement in APE changes by aspirin via the signaling pathway. Therefore, pulmonary artery pressure, pulmonary H&E and ELISA were used to quantitatively detect TNNI3, BNP and D2D levels in rat serum. The limitation of the study was that APE was mainly a mechanical obstruc-

Figure 6. Coexpression of CX3CL1/CX3CR1 and CX3CL1/nuclear factor-κB (NF-κB) as detected by laser confocal scanning microscopy. (A) CX3CL1/CX3CR1 coexpression; magnification x200. (B) CX3CL1/NF-κB coexpression.
tion of the pulmonary artery; neurohumoral (inflammatory mediator) control was not the key factor, and hence should not be emphasized, or a disconnection between experimental findings and clinical practice would result.

If therapy for APE is effective, it should significantly decrease the pulmonary artery pressure. When APE occurs, pulmonary artery pressure is increased. The present study found that HR, PASP, PADP and PAP in group M were significantly increased. Therefore, it was believed that the APE model was successful from the aspect of hemodynamics. The HR in group M+A was significantly decreased compared with group M, suggesting that aspirin took effect on APE. The pulmonary artery pressures in group M+A+SH and group M+A+CX3 was significantly decreased, indicating no overexpression or inhibition of CX3CL1; aspirin decreased the pulmonary artery pressure. It was confirmed by pulmonary H&E detection that only APE was affected by aspirin. Irrespective of the expression or inhibition of CX3CL1, the degree of APE and inflammation was less. The prognosis of APE is related to Th1, BNP and D2D (8). Therefore, these three indicators were used in the present study. After successful APE modeling, serum BNP and D2D were significantly increased. Furthermore, BNP was significantly decreased in M+SH, M+A+SH and M+A+CX3, and D2D was significantly decreased in M+SH, suggesting that the inhibition of CX3CL1 could improve the pathology of APE.

The European Society of Cardiology reported that APE is the most severe clinical manifestation of venous thromboembolism (VTE) (8). The basic process of APE includes mechanical obstruction. Pulmonary artery spasm contraction caused by neurohumoral factor (mainly inflammatory mediator) also plays an important role, especially within a short time. It mainly involves fibrous proteins and aggregated blood platelets, and also infiltration of various inflammatory cells. They continuously release a series of inflammatory mediators such as A2 (TXA2) (9) to shrink the pulmonary artery. More attention has been paid to the first step, and less to the second step.

CX3CL1 (fractalkine) is a chemotactic factor containing 373 amino acids. It possesses adhesive and chemotactic activity. It is the only member of the CX3C family (10), and can combine with a specific receptor CX3CR1, mediating the intimate adhesion of inflammatory cells and vascular endothelium cells. CX3CL1 plays an important role in the recruitment of inflammatory cells on the vascular wall and injury of endothelial cells (11,12). It was reported that TNF-α could influence the CX3CL1/CX3CR1 inflammatory signaling pathway (13), which was confirmed in a previous study (5). It was also demonstrated that the CX3CL1/CX3CR1 signaling pathway exists in atherosclerosis (14), and CX3CL1 plays a role in high pulmonary artery pressure combined with high airway pressure (15). However, still no systematic study exists on the mechanism underlying the involvement of CX3CL1/CX3CR1 in APE.

It was also confirmed that CX3CL1 was significantly increased in APE. Aspirin could inhibit the expression, as shown in this study. CX3CL1 in group Sham+CX3 was significantly increased and that in group M+SH was significantly decreased, suggesting that the preparations of CX3CL1 AD and shRNA AD were successful.

ICAM-1 is a member of the immunoglobulin superfamily (16). It is mainly expressed in neuronal cells, immune cells, vascular endothelium cells, epithelial cells, and glial cells. It is one of the important leukocyte-endothelial cell adhesion molecules, and is involved in intracellular and cell-matrix signal exchange, mediating adhesion, recognition, activation, proliferation, differentiation, inflammatory reaction and damage repair. After CX3CL1 overexpression in group Sham, the ICAM-A level was significantly higher than that in group N and group M, indirectly suggesting that CX3CL1 could stimulate the secretion of ICAM-1.
The TXA2 level in rats with APE was significantly increased, and the levels in groups M+SH, M+A and M+AH were significantly decreased. This indicated that aspirin could decrease TXA2 secretion after inhibiting CX3CL1 expression. The coexpression of CX3CL1/CX3CR1 and CX3CL1/NF-κB as detected by double immunofluorescent staining suggested increased expression of the aforementioned factors.

Therapy for APE includes streptokinase, urokinase, recombinant tissue plasminogen activator thrombolysis, low-molecular-weight heparin and new oral anticoagulants (18,19). The selection of aspirin was due to the inflammatory response after the occurrence of APE. It could irreversibly inhibit epoxidase and further inhibit the formation of thromboxane A2 in blood platelets. It could also inhibit the activation of NF-κB and exert anti-inflammatory effects. As nonsteroidal anti-inflammatory drugs are not specific, their high concentration may effectively inhibit inflammatory factors such as NF-κB (18,19). A previous study found that aspirin could inhibit NF-κB expression in APE (5). Aspirin inhibits CX3CL1/CX3CR1 expression (20,21). It can be safely applied in APE or for preventing deep vein thrombosis (22,23). The daily aspirin dose was required to be 325 mg for 14 days. Prevention and treatment of VTE was safe, thus the dose of aspirin was increased in the present study (24). This study demonstrated that aspirin improved the pathological changes in rats with APE via the CX3CL1/CX3CR1 signaling pathway.

Future studies should investigate the effect (and its underlying mechanism) of CX3CL1 on thrombogenesis by influencing the damage of vascular endothelium cells and inflammatory response.

Acknowledgements

The present study was funded by the Medical and Health Platform Program of Zhejiang Province (key support) (grant no. 2015ZDA022), Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents (2014-108) and the Natural Sciences Fund of Zhejiang Province (grant nos. LY17H290006 and LY12H29005).

References